Skip to main content

Month: June 2024

Kraig Biocraft Laboratories Announces Production Update for BAM-1 Spider Silk Hybrids

ANN ARBOR, Mich., June 11, 2024 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that production of its BAM-1 spider silk hybrid strain continues to set records for silkworm size, growth, and robustness. The Company announced in early June that it had accelerated its production schedule for its new BAM-1 hybrids based on the results of its spring production trials. The rearing of this first batch of production hybrids is now well underway. The Company is pleased to report that this is not only the largest single production batch in its history but also the strongest growing and most robust production batch the Company has produced. At more than ten times the size of the spring trials, this production batch is pushing the Company’s operational...

Continue reading

Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Approval in patients with pJIA weighing 63kg or greater adds to Kevzara’s position in treating adult chronic inflammatory conditions of moderately to severely active rheumatoid arthritis and polymyalgia rheumatica TARRYTOWN, N.Y. and CAMBRIDGE, MA, June 11, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration has approved Kevzara® (sarilumab) for the treatment of patients weighing 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA), a form of arthritis that impacts multiple joints at a time. “Polyarticular juvenile idiopathic arthritis can be a painful disease for children where multiple joints are impacted by this chronic infammation,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific...

Continue reading

Giyani Appoints Knight Piésold as Geoscience and Tailings Consultant for 2025 Definitive Feasibility Study

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) — Giyani Metals Corp. (TSXV:EMM, GR:A2DUU8) (“Giyani” or the “Company“) developer of the K.Hill battery-grade manganese project in Botswana (“K.Hill” or the “Project“) is pleased to announce that it has appointed Knight Piésold (Pty) Ltd (“Knight Piésold“) as lead Geoscience and Tailings Storage Facility (“TSF”) consultant on the Company’s Definitive Feasibility Study (“DFS”). Highlights:In addition to appointing Wood Plc as Lead DFS Consultant (see News Release (“NR”) dated June 04, 2024) Giyani has appointed another internationally recognised consultant Knight Piésold, as Lead Geoscience and TSF consultant for the DFS on Giyani’s K.Hill project. Knight Piésold is a global engineering group specifically selected by Giyani...

Continue reading

ConnectOne Bancorp, Inc. Adds Veteran Banking and Financial Services Consultant Susan O’Donnell to Board of Directors

Strategic Appointment Builds on Regional Bank’s Sustainable Growth Strategy ENGLEWOOD CLIFFS, N.J., June 11, 2024 (GLOBE NEWSWIRE) — ConnectOne Bank (“ConnectOne”), the wholly-owned depository subsidiary of ConnectOne Bancorp, Inc. (NASDAQ: CNOB), today announces the addition of seasoned financial services consultant Susan O’Donnell to its Board of Directors to deepen its bench of industry leaders from the financial services and banking industries. “Susan brings a strategic mindset to our board having advised banks and financial institutions over a 30-year career,” said Frank Sorrentino, Chairman and CEO of ConnectOne. “Her proven track record and leadership skills are a perfect match for us as we encounter the need to make tough strategic decisions to drive ConnectOne’s continued sustainable growth. We are proud to have Susan’s...

Continue reading

NFI subsidiary Alexander Dennis announces contract with Reading Buses for 53 buses including next-generation Enviro400EV electrics

LARBERT, United Kingdom, June 11, 2024 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI or the Company), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, subsidiary Alexander Dennis Limited (Alexander Dennis) today announced that it has confirmed new orders for 24 zero-emission and 29 low-emission buses for English bus operator Reading Buses. The 24 next-generation Alexander Dennis Enviro400EV double deckers will be the operator’s first batch of electric buses. They are the result of a successful bid with Reading Borough Council for funding from the second round of the UK Government’s Zero-Emission Regional Bus Areas scheme (ZEBRA 2). Fitted with the heavy-duty variant of the Voith Electrical Drive System (VEDS) and utilizing high-performance batteries...

Continue reading

Kaltura Announces Stock Repurchase Program

NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) — Kaltura, Inc. (“Kaltura” or the “Company”) (Nasdaq: KLTR), the Video Experience Cloud, today announced that its Board of Directors has authorized a stock repurchase program for up to $5 million of the Company’s common stock. “This repurchase authorization underscores the Board and Management’s strong conviction that our current share price is undervalued relative to our long-term opportunity. We remain committed to strategically deploying capital where we believe it can generate shareholder value,” said Ron Yekutiel, Chairman, President and Chief Executive Officer. Under the program, the Company may make repurchases, from time to time, through open market purchases, block trades, in privately negotiated transactions, accelerated stock repurchase transactions, or by other means. Open market...

Continue reading

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin (EFX) in patients with compensated cirrhosis, fibrosis stage 4 (F4) due to metabolic dysfunction-associated steatohepatitis (MASH). “Patients with compensated cirrhosis represent the greatest unmet need among MASH patients due to increased risk of progression to liver failure, hepatocellular carcinoma or death,” said Kitty Yale, chief development officer of Akero. “Based on the encouraging week 36 results of our Phase 2b SYMMETRY study in patients with compensated...

Continue reading

UK Businesses Fail to Unlock the Full Potential of their Employees, Survey Finds

The 2024 Kelly Global Re:work Report is now available. Discover what C-suite executives and employees at all levels think about the world of work today—and of the future. Get your copy here: https://mykelly.me/3KCrwk0UK executives most likely to say they are failing to unlock workforce potentialUK businesses least confident in their ability to recruit specialised talent Lack of skills development and career opportunities top frustrations for UK workersLONDON, June 11, 2024 (GLOBE NEWSWIRE) — Businesses in the United Kingdom are most likely to say they are failing to unlock the full potential of their employees and poor workforce planning is holding back growth for most organisations, a survey conducted in 13 countries by specialty talent solutions provider Kelly has found. The 2024 Kelly Global Re:work...

Continue reading

Losing Talent in the Age of AI: Global Survey Finds Businesses Fail to Unlock the Full Potential of their Employees

Kelly report discovers most talent strategies are ineffective, identifies workforce leaders defying trendsThe 2024 Kelly Global Re:work Report is now available. Discover what C-suite executives and employees at all levels think about the world of work today—and of the future. Get your copy here: https://mykelly.me/3KCrwk0TROY, Mich., June 11, 2024 (GLOBE NEWSWIRE) — Businesses are failing to unlock the full potential of their employees and poor workforce planning is holding back growth for most organizations, a global survey by specialty talent solutions provider Kelly has found. The 2024 Kelly Global Re:work Report reveals executives are turning to artificial intelligence (AI) and automation to solve these challenges but struggle to implement digital strategies effectively and neglect to offer adequate training...

Continue reading

Solaris Reports 81m of 0.73% CuEq within 544m of 0.50% CuEq from Surface; Announces Major Expansion of 2024 Drill Program Supported by Record Productivity

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) — Solaris Resources Inc. (TSX: SLS; NYSE: SLSR) (“Solaris” or the “Company”) is pleased to report additional drill results as its 2024 drilling program ramps up and a major expansion of planned meterage from 30km to 60km in this program. The expansion of the 2024 drilling program is supported by the closing of its recent financing and significant productivity improvements from past infrastructure investments and improved logistics and processes at its Warintza Project (“Warintza” or “the Project”) in southeastern Ecuador. Highlights are listed below, with a corresponding image in Figure 1 and results in Tables 1-2. HighlightsLatest drilling results include SLSE-33, collared on the southern margin of Warintza Southeast and drilled at a steep inclination northeast, returning...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.